deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02763319

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)

A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

Sponsor: Incyte Corporation

Updated 23 times since 2017 Last updated: Jul 15, 2025 Started: Nov 28, 2016 Primary completion: Jun 21, 2024 Completion: Jun 21, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Diffuse Large B-cell Lymphoma, this trial is completed. The trial is conducted by Incyte Corporation and has accumulated 23 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Sep 2017 · 2 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Aug 2025 · 3 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

23 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. May 2025 — Aug 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Sep 2024 — May 2025 [monthly]

    Completed PHASE2/PHASE3

  5. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Status: Active Not RecruitingCompleted

Show 18 earlier versions
  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  2. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Jan 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: RecruitingActive Not Recruiting

  5. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2_PHASE3

  6. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2_PHASE3

  7. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jul 2019 — Apr 2020 [monthly]

    Recruiting PHASE2_PHASE3

  9. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE2_PHASE3

  10. Oct 2018 — Apr 2019 [monthly]

    Recruiting PHASE2_PHASE3

  11. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE2_PHASE3

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2_PHASE3

  13. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  14. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE2_PHASE3

  15. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE2_PHASE3

  16. Jul 2017 — Sep 2017 [monthly]

    Recruiting PHASE2_PHASE3

  17. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2_PHASE3

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .